Search results
India’s ICMR selects four institutions for Phase I clinical trials
Clinical Trials Arena· 2 days agoThe Indian Council of Medical Research (ICMR) has selected four institutions to build a network of ...
Boehringer Ingelheim and Gubra begin Phase I trial of drug candidate for obesity
Clinical Trials Arena· 5 days agoBoehringer Ingelheim and Gubra have initiated a Phase I clinical trial of BI 3034701, a long-acting...
Sirnaomics concludes Phase I trial of pancreatic cancer treatment
Clinical Trials Arena· 6 days agoSirnaomics has concluded the Phase I clinical trial of a small interfering RNA (siRNA) therapeutic...
Delta-Fly Pharma starts subject enrolment in Phase III lung cancer trial
Clinical Trials Arena· 2 days agoIn April this year, Delta-Fly Pharma announced the US Food and Drug Administration's (FDA) approval...
HOOKIPA Pharma doses first subject in Phase Ib HIV treatment trial
Clinical Trials Arena· 5 days agoLast year, HOOKIPA dosed the first patient in a Phase I trial of HB-400, a non-replicating...
Avidity’s FSHD drug del-brax shows promise in Phase I/II trial
Clinical Trials Arena· 4 days agoThat’s what you want to see for drug development for a rare disease.” "Avidity’s FSHD drug del-brax...
NIH announces start of subject enrolment for nasal Covid-19 vaccine trial
Clinical Trials Arena· 5 days agoThe US National Institutes of Health (NIH) has announced the start of subject enrolment for a Phase ...
Developing a new biologic drug: regulatory challenges and considerations
Pharmaceutical Technology· 5 days agoThe journey from research lab to market is a long one, and most drug candidates do not make it. For...
CEPI announces plans for Nipah virus antibody trials
Clinical Trials Arena· 2 days agoCEPI will support the subsequent assessment of clinical safety testing led by ServareGMP and Mapp on concluding the Phase I ...
Sponsors must take on FDA’s diversity guidance to improve community trust
Clinical Trials Arena· 5 days agoWith data still showing that ethnic minorities account for less than 40% of US trial populations,...